Sicca Syndrome (Sjogren) Market

The global Sicca Syndrome (Sjogren) Market is valued at USD 174.3 Million in 2024 and is projected to reach a value of USD 259.8 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 3.8% between 2025 and 2035. The market is driven by the rising number of diagnosed autoimmune diseases globally.

Key Highlights

• Sjogren’s syndrome is a progressive autoimmune disorder characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands. This inflammation can occur independently, referred to as primary Sjögren’s syndrome, or alongside another autoimmune condition, known as secondary Sjögren’s syndrome
• Based on the Type, the Primary Sjogrens Syndrome category accounted for significant market share of 77.5% in 2024
• North America dominated the market with 38.2% market share in 2024

Type Overview

​The Type segment is divided into Primary Sjogrens Syndrome and Secondary Sjogrens Syndrome. The Primary Sjogrens Syndrome segment held the dominant share in 2024, accounting for significant market share of 77.5%.

Primary Sjögrens syndrome is a systemic autoimmune disorder that primarily affects the exocrine glands. Common symptoms include dryness of the mouth and eyes, and it is more frequently observed in women than in men. Women may also experience vaginal dryness. These symptoms, referred to as sicca symptoms, include xerophthalmia (dry eyes) and xerostomia (dry mouth). While various treatments are available to alleviate sicca symptoms, there is currently no cure for the condition. The presence of these symptoms contributes to a heightened demand for Sjögrens syndrome therapeutics, driving the growth of the market.

Application Overview

The Application segment is divided into Oral, Intravenous, Subcutaneous.

Oral: Medications taken by mouth, such as pills or capsules, are a common form of treatment for Sjogrens syndrome. Oral therapies are typically easy to administer and may include drugs that target immune modulation or symptom relief.

Intravenous (IV): Treatments administered directly into the bloodstream through an IV. This method is often used for biologics or other targeted therapies that require rapid absorption and effectiveness, particularly in more severe cases of Sjogrens syndrome.

Subcutaneous (SC): Medications given through injections under the skin. This route is frequently used for biologics and other therapies that patients can self-administer, providing a convenient option for long-term management of the condition.

Regional Overview

In 2024, the North America captured 38.2% of the revenue share.

North America Sicca Syndrome (Sjogren) market is driven by the rising prevalence of autoimmune disorders, driven by lifestyle changes such as low-fat diets, is fueling the Sjogrens syndrome therapeutics market. According to the Centers for Disease Control and Prevention (CDC), autoimmune diseases are the third most common category in the U.S. Additionally, the majority of clinical trials for Sjogrens syndrome treatments take place in North America, further supporting market growth. Anticipated FDA approvals of new therapeutic candidates during the forecast period will also contribute to the markets expansion in this region.

Asia Pacific region is anticipated to grow at fastest rate during the forecast period driven by increasing awareness of autoimmune diseases, improved healthcare infrastructure, and rising investments in medical research across countries like China, Japan, and India. The market is expanding faster since governments and the private sector in Asia Pacific are also making significant advancements in developing and approving innovative treatments.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Regions and Countries

North America

• The US
• Canada
• Rest of North America

Europe

• Germany
• France
• The UK
• Spain
• Netherlands
• Russia
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• Singapore
• Thailand
• South Korea
• Vietnam
• India
• New Zealand
• Rest of Asia Pacific

Latin America

• Mexico
• Brazil
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• South Africa
• UAE
• Rest of the Middle East & Africa

Key Trends

• Growing focus on biologic therapies: Increased interest in developing biologics targeting the immune response in Sjogren’s Syndrome
• Advances in immune-modulating treatments: Research into therapies that modulate the immune system is gaining momentum
• Personalized medicine approaches: Tailored treatments based on individual patient profiles are becoming more prominent
• Improved diagnostic tools: Advances in biomarkers and classification criteria are enhancing early detection and patient stratification
• Rise of digital health technologies: Digital tools for disease monitoring and management are becoming more integrated into patient care

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

The growing number of promising drug candidates in development is expected to boost the market

The robust pipeline of new therapies like lanalumab suggests that more effective treatment options could soon be available, driving growth in the Sjogren’s syndrome market. For instance, data published in July 2022 by the National Institute of Health (NIH) highlights a Phase 3 clinical trial that is underway to evaluate the safety and effectiveness of lanalumab in treating patients with Sjogren’s syndrome. It is anticipated that this multi-center, randomized, double-blind, placebo-controlled trial will be finished by March 2026.

Development of new therapies for Sjögren’s syndrome presents substantial financial challenges, acting as a significant restraint on the market

It usually takes a large financial investment, frequently in the hundreds of millions or even billions of dollars, to research a new medicine. This includes a range of stages, such as preclinical research, early-stage research, and several stages of clinical trials. For conditions like Sjögren’s syndrome, which have a relatively small patient population, the high costs can deter pharmaceutical companies from investing in research and development. Additionally, the complexity of conducting clinical trials, which often involve lengthy durations and large patient cohorts, can further escalate expenses.

Competitive Landscape

The Sicca Syndrome (Sjogren) market is evolving with several key players driving R&D efforts to address this complex autoimmune disorder. Prominent pharmaceutical corporations, including as Johnson & Johnson, Novartis, and GSK, are proactively engaged in the advancement of innovative treatments that address multiple facets of the illness, such as immune regulation and inflammation. Clinical trials for biologics, such as nipocalimab, and other novel medicines are ongoing with the goal of providing patients with more individualized and efficacious therapy alternatives.

Company List:

• Bristol-Myers Squibb Co
• Biogen Inc
• AbbVie Inc
• Novartis AG
• ADVANZ PHARMA Corp. Ltd
• Sanofi SA
• Hikma Pharmaceuticals Plc
• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson
• Daiichi Sankyo Co. Ltd

Recent Market Developments

• In June 2024, Johnson & Johnsons drug nipocalimab has demonstrated potential in a clinical trial for Sjögren’s disease, showing a significant and clinically important improvement in ClinESSDAI scores compared to a placebo